Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicentre, International Neoadjuvant Randomized Double-blind Trial Comparing Fulvestrant to a Combination of Fulvestrant and Palbociclib (CDK 4/6 Inhibitor) in Patients With Operable Luminal Breast Cancer Responding to Fulvestrant

Next Previous
Search
Trial Profile

Multicentre, International Neoadjuvant Randomized Double-blind Trial Comparing Fulvestrant to a Combination of Fulvestrant and Palbociclib (CDK 4/6 Inhibitor) in Patients With Operable Luminal Breast Cancer Responding to Fulvestrant

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fulvestrant (Primary) ; Goserelin (Primary) ; Palbociclib (Primary)
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Acronyms SAFIA

    • Most Recent Events

    • 01 Aug 2023 Results assessing efficacy of neoadjuvant palbociclib in advanced breast cancer patients were published in the Journal of Cancer Research and Clinical Oncology
    • 03 Aug 2022 Status changed from active, no longer recruiting to completed.
    • 07 Jun 2022 Status changed from recruiting to active, no longer recruiting as per results presented at the 58th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top